UNSPSC 51202405: Certolizumab

This classification denotes a monoclonal antibody, which generally arises as C19H30N5O8S(C2H4O)n(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6ADW90R16. European Medicines Agency schedules Certolizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25456. The term CERTOLIZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, list 52.) As of Q4 2014, CERTOLIZUMAB remains US FDA's Preferred Term for this commodity.

Certolizumab bears US NLM identifiers UMLS ID CL430555 and NCI Concept Code C97947. SMILES: none.

UNSPSC 51202405 Certolizumab is a Commodity code that nominally identifies a specific immunosuppressant pharmaceutical, but recent state and local solicitations show limited activity aligned with this product code. The recent opportunities block contains four records: one IFB for naloxone and drug deactivation systems (Seminole County, Florida), one RFI for direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), one IFB for medical and first aid supplies (City of Tampa), and one RFP for generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations reference certolizumab or biologics in the immunosuppressant class; instead, they address emergency response consumables, pharmacy benefit program design, medical supply chains, and generic pharmaceutical distribution. The code appears to see little relevant recent activity aligned to its nominal scope.

State and local procurement of pharmaceuticals more broadly spans county health departments, state human services agencies, municipal fire departments, and multi-state cooperative purchasing organizations, though these recent opportunities do not cluster around the specific product this code identifies. Geographic activity in the recent block includes Florida, Texas, and Minnesota, representing a dispersed pattern across regions rather than concentrated procurement in any single state or jurisdiction. The mismatch between the code's pharmaceutical specificity and the actual scope of recent solicitations suggests that either the code is misapplied to these opportunities or that certolizumab itself does not generate measurable state and local demand at the present time. Business development professionals should confirm whether certolizumab procurement activity exists outside these recent records or whether the code is being used inconsistently across state and local procurement systems.